Previous Close | 9.40 |
Open | 9.40 |
Bid | 9.40 |
Ask | 10.70 |
Strike | 80.00 |
Expire Date | 2025-01-17 |
Day's Range | 9.40 - 9.40 |
Contract Range | N/A |
Volume | |
Open Interest | 1.83k |
FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in rural Kenya during the height of the HIV epidemic in sub-Saharan Africa. After graduating from medical school at the University of Nairobi, he decided to begin his career ...